The treatments that may change the heart failure management
This is an incredible moment in heart failure research because there are more new treatments being tested in Phase III large scale morbidity and mortality trials than ever before. These new treatments may change the future management of patients with heart failure as well as the current guidelines, if the trials are successful.
This is an incredible moment in heart failure research because there are more new treatments being tested in Phase III large scale morbidity and mortality trials than ever before. These new treatments may change the future management of patients with heart failure as well as the current guidelines, if the trials are successful.
ESC 2017
The treatments that may change the heart failure management
en
Prof. John Mc Murray
TAVI is noninferior to surgery in medium risk patients
en
Prof. Corrado Tamburino
Aggiornate le raccomandazioni per l'impiego della TAVI
it
Prof. Corrado Tamburino
The treatment effect of renal denervation has been demonstrated
en
Prof. Michael Böhm
REVEAL trial: clinical effects of anacetrapib in established VD
en
Prof. Martin Landray
Benefits and risks of taking Aspirin lifelong
en
Clinical efficacy and safety of achieving very low LDL levels
it
Robert Giugliano, MD
Empaglifozin and Liraglutide for the CVD in type 2 diabetes
en
Prof. Lars Ryden
Linee guida ESC: trattamento TAVI anche per il rischio intermedio
it
Prof. Ciro Indolfi
Prasugrel vs Clopidogrel in over 75 after angioplasty
en
Prof. Stefano De Servi
Prasugrel vs Clopidogrel negli over 75 dopo angioplastica
it
Prof. Stefano De Servi
Study reveals: LDL lowering depends on how it is lowered
en
Prof. Brian A Ference
Is Ticagrelor really superior to Clopidogrel?
en
Prof. Clemens v. Birgelen
The REVEAL trial design
en
Prof. Louise Bowman
PURE study results: fruit and vegetables intake, CVD and deaths
en
Dr. Andrew Mente